سامية محمد مصطفى



شبكة المعلومات الحامعية

# بسم الله الرحمن الرحيم



-Caro-

سامية محمد مصطفي



شبكة العلومات الحامعية



شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم





سامية محمد مصطفى

شبكة المعلومات الجامعية

# جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

## قسو

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة يعيدا عن الغيار



سامية محمد مصطفي



شبكة المعلومات الجامعية



المسلمة عين شعور المسلمة عين شعور المسلمة عين شعور المسلمة عين شعور المسلمة ا

سامية محمد مصطفى

شبكة المعلومات الحامعية



بالرسالة صفحات لم ترد بالأصل



### FAS EXPRESSION IN SOME COMMON **CUTANEOUS NEOPLASMS**

THESIS

Submitted to the Faculty of Medicine, Tanta University in Partial Fulfillment of the requirements of the Master Degree

**Dermatology & Venereology** 

By

Mervat Osman Tawfeik Hafez

(M.B.,B. Ch.,)

Supervisors Prof. Dr.

Moustafa H. Abd El-Maksoud

Prof. of Dermatology and Venereology Faculty of Medicine Tanta University

Prof. Dr.

Hussein M. Ghoraba

Prof. of Pathology Faculty of Medicine Tanta University

Prof. Dr.

Iman H. El- Maadawy

Prof. of Dermatology and Venereology Faculty of Medicine Tanta University

FACULTY OF MEDICINE TANTA UNIVERSITY

2001

بسم الله الرحمن الرحيم قالوا سبحانك لاعلم لنا إلا فأعلمتنا إنك أنت العليم الدكيم

صدق الله العظيم

" البقرة ٣٢"

#### ACKNOWLEDGEMENT

I always feel indebted to **ALLAH** whose blessings on me can not be counted

I would like to express my deepest gratitude to **Prof. Dr.**Moustafa Hussein. Abd El-Maksoud Professor of Dermatology & Venereology, Faculty of Medicine Tanta University, for his continuous help and guidance and kind cooperation throughout this work. He patiently guided me, provided me most readily and generously with his valuable relevant views, which kept me on the rightway.

I owe special feeling of gratitude to **Prof. Dr. Hussein Mohamed Ghoraba**, Professor of Pathology, Faculty of Medicine
Tanta University, for his great help and experienced guidance through
the period of the work.

Great thankfulness and indebtedness to **Prof. Dr. Iman Hamed El-Maadawy.** Professor of Dermatology & Venereology,

Faculty of Medicine Tanta University, for her great help, unlimited support, meticulous supervision and encouragement throughout this work.

Great thankfulness and indebtedness to **Dr. Mayada Abd El- Fattah Ismail**, Lecturer. of Dermatology & Venereology, Faculty of Medicine Tanta University, for her help throughout this work.

My gratitude and thanks are offered to all staff members and colleagues in the Dermatology and Venereology Department, Faculty of Medicine, Tanta University, who helped and advised me during this work.

My thanks and my best wishes to my patients without whom this work could not be possible.

#### **ABBREVATIONS**

**Ab:** Antibody

**ACTH:** Adrenocorticotrophic hormone.

Ag: Antigen

AIDS: Acquired immunodeficiency syndrome.

APCs: Antigen-presenting cells.

**Apo-1:** Apoptotic gene 1.

Bcl-2: B-cell leukaemia/lymphoma-2.

Bcl-x<sub>L</sub>: Bcl-x long form.

Bag1: Bcl-2 associated athanogene 1.

Bak: Bcl-2 homologous antagonist killer.

Bax: Bcl-2-associated x protein.

BCCs: Basal cell carcinomas.

BHRF1: Latent membrane protein.

**c-DNA:** Complementary deoxyribonucleic acid.

**C-myc:** Cellular myelocytomatosis.

**COOH:** Carboxyl group.

CTL: Cytotoxic T-lymphocyte.

**EBV:** Epstein Barr virus.

EGF-R: Epidermal growth factor receptor.

**EIA:** Transforming protein encoded by cowpox virus.

**Fas:** Fatty acid synthase.

FasL: Fas ligand.

**FADD:** Fas associated protein with a death domain.

**GF:** Growth factor.

Gld: Generalized lymphoproliferation disease.

**GVHD:** Graft-versus-host disease.

HGFs: Haematopoietic growth factors.
HIV: Human Immunodeficiency virus.

ICE: Interleukin-1 converting enzyme.

**IFNs:** Interferons

**IL-2R:** Interleukin-2 receptor.

II.s: Interleukins.

Ipr: Lympho-proliferation.

Kb: Kilobase.

KD: Kilo dalton.

LMP: Latent membrane protein.

LMW: Low molecular weight.

**LT-α:** Lymphotoxin alpha.

**LT** -β: Lymphotoxin beta

MF: Mycosis fungoides

MHC: Major histocompatibility complex.

MMs: Malignant melanomas.

mRNA: Meassenger ribonucleic acid.

**NGF:** Nerve growth factor.

NGF-R: Nerve growth factor receptor.

NH<sub>2</sub>: Nitrogenous group.

NK: Natural killer.

**P53:** 53 kilodalton phosphoprotein.

P55: Surface Protein 55.
P75: Surface Protein 75

**PBS:** Phosphate buffer solution

**PDGF:** Platelet derived growth factor.

**PGs:** Prostaglandins.

**pRb:** Rhinoblastoma protein.

**r-TNF-**α: Recombinant tumour necrosis factor alpha.

r-TNF-s: Recombinant tumour necrosis factor-s.

SCCs: Squamous cell carcinomas.

**SIL:** Systemic lupus erythematosis.

TCR: T-cell receptor.

**TGF-** $\beta$ 1: Transforming growth factor Beta 1.

**TGF**-β: Transforming growth factor beta.

T<sub>H</sub>: T helper.

**TNF:** Tumour necrosis factor.

TNF-α: Tumour necrosis factor alpha.

TNF-β: Tumour necrosis factor beta.

TNF-Rs: Tumour necrosis factor receptors.

TNFR-RP: Tumour necrosis factor receptor -related protein.

**TRADD:** Tumour necrosis factor receptor adaptor death domain.

**UV:** Ultraviolet.

#### LIST OF TABLES

Table no.	Title	Page
. 1	Tumour necrosis factor receptor superfamily	6
	members and their ligands	
2	Target cells and actions of IL-1 and TNF.	8
3	Localization of Fas and FasL mRNA in 16.5	21
	and 18.5-d-old Mouse Embryos.	
4	Expression of Fas and Fas ligand (FasL) in	22
	normal human skin.	
5	Genes that regulate apoptosis in mammalian	46
	cells.	
6	Anamnestic data of the studied cases.	60
7	Expression of Fas antigen on the skin tumours	60
8	Expression of Fas antigen on normal human	62
·	skin	
9	Sites and clinical types of SCC.	65
10	Relation between histopathological grading of	65
	SCCs and intensity of Fas expression.	
11	Sites and clinical types of BCC.	70
12	Histopathological types of BCC.	70
13	Sites and clinical types of MF.	74
14	Sites and clinical types of MM.	78
15	Relation between staging of MMs and intensity	79
	of Fas expression.	

#### LIST OF FIGURES

Fig. no.	Title	Page
1	Schematic representation of surface protein 55 (p55) and	5
	P75 TNF-R.	9
2	Actions of TNF on haematopoietic and lymphoid tissues.	10
3	Actions of TNF on non lymphoid cell tissues.	14
4	The TNF and NGF receptor family and similarity with	
_	Fas	15
5	Nucleotide sequence and predicted amino-acid sequence	70
	of human Fas antigen complementary deoxyribonucleic	
	acid (cDNA)	17
6	The TNF family and FasL.	18
7	Nucleotide sequence and predicted amino-acid sequence	***
· .	of rat FasL c-DNA.	24
8	A model of Fas mediated signalling, caspase activation	2-1
	and the induction of a death signal. FADD,	
	Fas-associating protein with a death domain.	27
9	A model for Fas-mediated clonal deletion.	31
10	A schematic representation of two major pathways of	31
	T-cell-mediated cytotoxicty.	37
11	The stages of apoptosis in a lymphocyte.	37
12	Pathway of cell death.	07
13	Common metabolic events in apoptosis.	37
14	Acquired capabitities of cancer, it is suggest that most if	38
	not all cancers have acquired the same set of functional	48
	capabilities during their development, albeit through	,
	various mechanistic strategies.	CO
15	Normal control showing the epidermal cell layers and	63
	dermis	CO
16	Normal skin showing marked positive reaction in the	63
	basal layer (+++) and moderate reaction (++) in the	
	spinous layer.	

Fig. no.	Title	Page
17	Squamous cell carcinoma (noduloulcerative type) on the	66
	nasolabial fold extending to nose and cheek.	
18	Squamous cell carcinoma (grade I) showing tumour horn	66
	pearls	077
19	Squamous cell carcinoma (grade II) showing positive	67
	(+++) Fas expression in the tumour cells (arrows) and	
	in the inflammatory cells (dots).	67
20	Squamous cell carcinoma (grade IV) showing positive (+)	67
	Fas expression (arrows) in tumour cells.	771
21	Nodulo-ulcerative basal cell carcinoma on the inner	71
	canthus of the eye extending to the nose	71
22	Basal cell carcinoma (solid type) showing nests of	* *
	basalioma cells.	72
23	Basal cell carcinoma (solid type) showing nests of	
	basalioma cells.  Basal cell carcinoma (solid type) showing negative	72
24	staining for Fas in the tumour cells and positive (++)	
	staining (arrows) in the inflammatory cells.	
25	Tumour stage mycosis fungoides on the back and	75
25	extremities.	
26	Mycosis fungoides (tumour stage) showing dermal	76
20	atypical lymphocyte (arrows).	
27	Mycosis fungoides showing negative Fas expression in	76
	the tumour cells with marked (+++) positivity in the	
	keratinocytes	
28	Malignant melanoma on the sole.	80
29	Malignant melanoma showing hyperpigmented atypical	80
	melanocytes (dots) with some mitotic figures (arrows)	
30	Malignant melanoma (stage 1 B) showing marked (+++)	81
	Fas expression in tumour cell nests	
31	Malignant melanoma (stage II B) showing focal moderate	81
	(++) Fas expression in tumour (arrows) and	
	inflammatory cells (dots)	

THOMAS LANGE STREET,

1

### CONTENTS

INTRODUCTION	1
AIM OF THE WORK	2
REVIEW OF LITERATURE	3
O Tumour necrosis factor and tumour necrosis factor receptors	3
O Fatty acid synthase (FAS)	13
O Apoptosis	
O Cracinogenesis	47
PATIENTS AND METHODS	<b>5</b> 6
RESULTS	60
DISCUSSION	82
SUMMARY ND CONCLUSIONS	96
REFERENCES	99
AD ADYO CITATA ADV	

